

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Hiroaki MAKINO	09/27/2005
Mika TAKAKUWA	09/27/2005
Gen UNOKI	09/27/2005
Kenichiro KATAOKA	09/27/2005
Dale Robert MITCHELL	09/29/2005
Donald James SIMPSON	09/27/2005
Clifford John HARRIS	10/05/2005
Joelle LE	09/27/2005
Yuko YAMAKOSHI	09/27/2005
Tomomi KOSUGI	09/27/2005
Minoru IMAI	09/27/2005

RECEIVING PARTY DATA

Name:	TEIJIN PHARMA LIMITED
Street Address:	1-1, Uchisaiwaicho 2-chome
City:	Chiyoda-ku, Tokyo
State/Country:	JAPAN
Postal Code:	100-0011

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11202035

CORRESPONDENCE DATA

Fax Number: (202)293-7860

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202-293-7060

Email: jrosenberg@sughrue.com

Correspondent Name: Susan J. Mack

CH \$40.00 11202035

500080237

PATENT
REEL: 017201 FRAME: 0506

Address Line 1:	2100 Pennsylvania Avenue, N.W.
Address Line 2:	Suite 800
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20037

ATTORNEY DOCKET NUMBER:	Q93215
-------------------------	--------

NAME OF SUBMITTER:	Susan J. Mack
--------------------	---------------

Total Attachments: 2 source=q83215assgn#page1.tif source=q83215assgn#page2.tif
--

Assignment

Whereas, I/We, (1) Tomomi KOSUGI (2) Minoru IMAI (3) Hiroaki MAKINO
(4) Mika TAKAKUWA (5) Gen UNOKI (6) Kenichiro KATAOKA
(7) Dale Robert MITCHELL (8) Donald James SIMPSON (9) Clifford John HARRIS
(10) Joelle LE (11) Yuko YAMAKOSHI

(1),(2),(3),(4),(5),(6) and (11) of c/o Teijin Pharma Limited,, Tokyo Research Center, 3-2,
Asahigaoka 4-chome, Hino-shi, TOKYO, 191-0065 JAPAN
(7),(8),(9) and (10) of c/o BioFocus, Chesterford Park Saffron Walden, Essex, CB10 1XL, UK

hereinafter called assignor(s), have invented certain improvements in
PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

and executed an application for Letters Patent of the United States of America therefor on
September 27, 29 and October 5, 2005 ; and

Whereas, TEIJIN PHARMA LIMITED, 1-1, Uchisaiwaicho 2-chome, Chiyoda-ku,
TOKYO 100-0011 JAPAN

(assignee), desires to acquire the entire right, title, and interest in the application and
invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named
assignee, its successors and assigns, the entire right, title and interest in the application and the
invention disclosed therein for the United States of America, including the right to claim priority
under 35 U.S.C. §119, and I/we request the Director – U.S. Patent and Trademark Office to issue
any Letters Patent granted upon the invention set forth in the application to the assignee, its
successors and assigns; and I/we will execute without further consideration all papers deemed
necessary by the assignee in connection with the United States application when called upon to
do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100
Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses
(Application number 11/202,035 and Confirmation number
7330, filed August 12, 2005) the filing date
and application number of said application when known.

①	Date:	小杉 知巳	SEP. 27. 2005
		s/ Tomomi KOSUGI	
②	Date:	<i>Minoru Imai</i>	SEP. 27. 2005
		s/ Minoru IMAI	
③	Date:	牧野 弘明	SEP. 27. 2005
		s/ Hiroaki MAKINO	
④	Date:	高桑 美香	SEP. 27. 2005
		s/ Mika TAKAKUWA	
⑤	Date:	鶴木 元	SEP. 27. 2005
		s/ Gen UNOKI	
⑥	Date:	片岡 健一郎	SEP. 27. 2005
		s/ Kenichiro KATAOKA	
⑦	Date:	<i>Dale Robert Mitchell</i>	29/09/05
		s/ Dale Robert MITCHELL	
⑧	Date:	<i>Donald James Simpson</i>	27/09/05
		s/ Donald James SIMPSON	
⑨	Date:	<i>Clifford John Harris</i>	5/10/05
		s/ Clifford John HARRIS	
⑩	Date:	<i>Joelle Le</i>	27/09/05
		s/ Joelle LE	
⑪	Date:	太田 優子	SEP. 27. 2005
		s/ Yuko YAMAKOSHI	

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)